Post-COVID Rheumatic and Immune-Mediated Diseases
A special issue of Rheumato (ISSN 2674-0621).
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 3412
Special Issue Editors
Interests: COVID; rheumatic manifestations; post-infectious autoimmune diseases; systemic sclerosis; gout; CPPD
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The potential role of viruses in the development of rheumatic diseases is well recognized, either as causative agents or as antigenic triggers for the development of autoimmunity. Inflammatory musculoskeletal manifestations following COVID-19 have been described since the earliest phases of the pandemic. Since symptoms of potential rheumatologic interest have been frequently reported in COVID-19 patients, the new virus outbreak represents a previously unseen differential diagnosis to be henceforth taken into consideration, and a “post-COVID-19 syndrome” with rheumatological manifestations is increasingly recognized as a potential complication of SARS-CoV-2 infection. Furthermore, inflammatory musculoskeletal symptoms may occasionally develop in close temporal association with COVID-19 vaccine administration. Previous studies assumed a possible association between the onset of autoimmune inflammatory diseases and vaccinations. Adjuvants may be responsible for inducing post-vaccination adverse events, in the so-called ‘ASIA’ syndrome, which represents a spectrum of presumably immune-mediated diseases secondary to the exposure to an adjuvant, associated with individual genetic predisposition.
This Special Issue aims to provide an overview of the spectrum of post-COVID-19 or post-COVID-19 vaccination rheumatic and immune-mediated diseases.
Dr. Jacopo Ciaffi
Dr. Francesco Ursini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Rheumato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- post-infection
- vaccination
- inflammatory
- immune-mediated
- rheumatic
